Prevalence of circulating tumor cells in localized prostate cancer.
Publication/Presentation Date
11-1-2013
Abstract
BACKGROUND: Circulating tumor cells (CTC) predict overall survival in patients with metastatic prostate cancer. The objective of this study is to measure CTC before radical prostatectomy in intermediate- and high-risk prostate cancer patients.
MATERIALS AND METHODS: The study accrued 12 patients and 10 provided adequate peripheral blood sample. Blood was drawn preoperatively and assayed for CTC using the CellSearch system. Patients were categorized as CTC positive (≥ 1 CTC) or CTC negative (no CTC).
RESULTS: Median age was 64.5 years (range 49-77 years), median prostate specific antigen was 7.4 ng/ml (range 5.7-25.7 ng/ml). Seven patients had intermediate-risk and 3 patients had high-risk prostate cancer. One patient was found to be CTC positive.
CONCLUSIONS: Our pilot study shows that CTC are rare in patients with clinically localized disease despite intermediate- to high-risk features. CTC may not be the optimal marker to predict prognosis or detect residual disease after radical prostatectomy.
Volume
7
Issue
2
First Page
65
Last Page
69
ISSN
1661-7649
Published In/Presented At
Khurana, K. K., Grane, R., Borden, E. C., & Klein, E. A. (2013). Prevalence of circulating tumor cells in localized prostate cancer. Current urology, 7(2), 65–69. https://doi.org/10.1159/000356251
Disciplines
Medicine and Health Sciences
PubMedID
24917761
Department(s)
Department of Medicine
Document Type
Article